This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Need Defense? Think Medical Supplies

Diversification won't be easy, because competitors in diagnostics and biosciences such as Abbott (ABT) and Roche have "greater marketing reach and larger R&D budgets," Morozov warns.

However, Becton Dickinson's "reputation for searching out pockets of growth, along with its sizable manufacturing and distribution infrastructure, convinces us that [it] will be able to fend off competition," Morozov says. He gives the stock a three-star rating on a scale of one (sell) to five (buy).

Buy and Build

Bard also will need some bolt-on deals to help propel sales and profits, says Kristen Stewart of Credit Suisse. In the last two years, Bard has bought businesses that make non-heart stents, a device that prevents catheters and intravenous tubes from falling out of a patient's body, and safety needles and syringes.

Stewart told clients in a March 10 report that Bard will probably make more small acquisitions. "Given the current conditions in the credit and equity markets, as well as the regulatory and reimbursement environment, we believe larger med-tech companies may be able to acquire smaller companies at reasonable valuations."

Stewart, who has a neutral rating, says the current stock price more than reflects Bard's growth rate prospects. She doesn't own shares, but her firm is a market maker. She and other analysts say Bard has become a star thanks to a big deal that didn't happen. The voracious conglomerate Tyco International (TYC) bid for Bard in May 2001, but the deal fell through in February 2002.

After the deal unraveled, Bard restructured, developed new products and accelerated sales and profit growth. "The company initially fell into its standard pattern" of 6% to 8% sales growth, says Matthew Dodds of Citigroup Global Markets, in a March report to clients. The emergence of new products pushed the sales growth rate past 10% and the earnings-per-share rate over 15% for several years, says Dodds, who has a buy rating.

Another surge of new products, starting two years ago, should keep Bard in "double-digit sales and mid-teens EPS growth through 2010," says Dodds, who doesn't own shares. His firm has had a non-investment-banking relationship. Bard is "one of the safest, most diversified companies in med-tech," says Dodds.

Analysts say Bard must beware of Covidien (COV), which was spun off in mid-2007 from Tyco. Covidien represents Tyco's spending spree for medical-device, drug, radiation and surgical-products companies.

With a market cap of about $23 billion, Covidien is a major force in medical devices, which account for nearly 70% of sales from continuing operations. However, it may take two years for Covidien to really get rolling, because it must undo the damage caused by Tyco.

Tyco, analysts say, paid inadequate attention to its health care properties, starving them for financial support and treating them merely as cash generators. "Covidien's near-term profitability will be negatively impacted by growing marketing and R&D costs," Morozov told subscribers in February.

Covidien also was saddled with $144 million in unresolved tax liabilities "and a long list of outstanding legal proceedings," he says. Morozov gives Covidien a four-star rating, because "we view these as temporary hurdles."

Since its spinoff, Covidien has sold, or announced plans to sell, three businesses and has bought two small device-makers. Analysts expect more wheeling and dealing.

"Covidien is on the right track pruning noncore businesses and building on its core medical technology franchises," says Joanne Wuensch of BMO Capital Markets, in a March 12 note to clients. Wuensch, who doesn't own shares, has a market perform rating.

Between July 2, 2007, the first formal trading day on the NYSE, and April 2, 2008, Covidien's stock was up 5%.

2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,982.59 +22.02 0.13%
S&P 500 1,978.91 +0.57 0.03%
NASDAQ 4,444.9090 -4.6550 -0.10%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs